Market Cap (In SEK)
53.46 Million
Revenue (In SEK)
5.54 Million
Net Income (In SEK)
-35.66 Million
Avg. Volume
19.87 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.27-4.3
- PE
- -
- EPS
- -
- Beta Value
- 1.526
- ISIN
- SE0016101935
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Peter Ekolind
- Employee Count
- -
- Website
- https://www.combigene.com
- Ipo Date
- 2015-05-25
- Details
- CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
More Stocks
-
6725
-
0303
-
002559
-
2673
-
FAIRCHEMORFairchem Organics Limited
FAIRCHEMOR
-
004490
-
GRG
-
0R6H